首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Effects of the Antifungals Voriconazole and Fluconazole on the Pharmacokinetics of S-(+)- and R-(−)-Ibuprofen
【2h】

Effects of the Antifungals Voriconazole and Fluconazole on the Pharmacokinetics of S-(+)- and R-(−)-Ibuprofen

机译:抗真菌药伏立康唑和氟康唑对S-(+)-和R-(-)-布洛芬药代动力学的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Our objective was to study the effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of S-(+)- and R-(−)-ibuprofen. Twelve healthy male volunteers took a single oral dose of 400 mg racemic ibuprofen in a randomized order either alone, after ingestion of voriconazole at 400 mg twice daily on the first day and 200 mg twice daily on the second day, or after ingestion of fluconazole at 400 mg on the first day and 200 mg on the second day. Ibuprofen was ingested 1 h after administration of the last dose of voriconazole or fluconazole. Plasma concentrations of S-(+)- and R-(−)-ibuprofen were measured for up to 24 h. In the voriconazole phase, the mean area under the plasma concentration-time curve (AUC) of S-(+)-ibuprofen was 205% (P < 0.001) of the respective control value and the mean peak plasma concentration (Cmax) was 122% (P < 0.01) of the respective control value. The mean elimination half-life (t1/2) was prolonged from 2.4 to 3.2 h (P < 0.01) by voriconazole. In the fluconazole phase, the mean AUC of S-(+)-ibuprofen was 183% of the control value (P < 0.001) and its mean Cmax was 116% of the control value (P < 0.05). The mean t1/2 of S-(+)-ibuprofen was prolonged from 2.4 to 3.1 h (P < 0.05) by fluconazole. The geometric mean S-(+)-ibuprofen AUC ratios in the voriconazole and fluconazole phases were 2.01 (90% confidence interval [CI], 1.80 to 2.22) and 1.82 (90% CI, 1.72 to 1.91), respectively, i.e., above the bioequivalence acceptance upper limit of 1.25. Voriconazole and fluconazole had only weak effects on the pharmacokinetics of R-(−)-ibuprofen. In conclusion, voriconazole and fluconazole increased the levels of exposure to S-(+)-ibuprofen 2- and 1.8-fold, respectively. This was likely caused by inhibition of the cytochrome P450 2C9-mediated metabolism of S-(+)-ibuprofen. A reduction of the ibuprofen dosage should be considered when ibuprofen is coadministered with voriconazole or fluconazole, especially when the initial ibuprofen dose is high.
机译:我们的目的是研究抗真菌药伏立康唑和氟康唑对S-(+)-和R-(-)-布洛芬的药代动力学的影响。 12位健康的男性志愿者在服用伏立康唑的第一天每天两次,每天两次两次,每天200 mg,第二天,每天两次,或者在服用氟康唑之后,一次随机服用400毫克消旋布洛芬的单次口服剂量。第一天400毫克,第二天200毫克。给予最后剂量的伏立康唑或氟康唑1小时后,摄入布洛芬。测量血浆中S-(+)-和R-(-)-布洛芬的浓度长达24小时。在伏立康唑相中,S-(+)-布洛芬的血药浓度-时间曲线(AUC)下的平均面积为相应对照值的205%(P <0.001),平均血药峰值浓度(Cmax)为122各自控制值的%(P <0.01)。伏立康唑将平均消除半衰期(t1 / 2)从2.4小时延长至3.2小时(P <0.01)。在氟康唑阶段,S-(+)-布洛芬的平均AUC为对照值的183%(P <0.001),平均Cmax为对照值的116%(P <0.05)。氟康唑将S-(+)-布洛芬的平均t1 / 2从2.4小时延长至3.1小时( P <0.05)。伏立康唑和氟康唑相的几何平均 S -(+)-布洛芬AUC比为2.01(90%置信区间[CI],1.80至2.22)和1.82(90%CI,1.72至1.91) ),即高于生物等效性接受上限1.25。伏立康唑和氟康唑对 R -(-)-布洛芬的药代动力学只有微弱的影响。总之,伏立康唑和氟康唑分别增加了 S -(+)-布洛芬的2倍和1.8倍的暴露水平。这可能是由于抑制细胞色素P450 2C9介导的 S -(+)-布洛芬代谢所致。当布洛芬与伏立康唑或氟康唑合用时,应考虑降低布洛芬剂量,尤其是当布洛芬初始剂量较高时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号